# A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct07623616/  
OnCo record `nct07623616` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ziftomenib in acute myeloid leukaemia, run by Kyowa Kirin Co., Ltd., now recruiting.

## Summary

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia is a phase 2 interventional study registered as NCT07623616 by Kyowa Kirin Co., Ltd., with 6 participants planned, started 2026-04-23 and due to reach its primary completion in 2027-03. Interventions recorded: ziftomenib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07623616
- Phase: 2
- Setting: A Phase 2, Multicenter, Open-Label Study of Ziftomenib Monotherapy in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia With NPM1 Mutation
- Sponsor: Kyowa Kirin Co., Ltd.
- Enrolled: 6

## Sources

- ClinicalTrials.gov NCT07623616: https://clinicaltrials.gov/study/NCT07623616

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Ziftomenib](https://onco.cc/drugs/ziftomenib/)
- companies: [Kyowa Kirin](https://onco.cc/companies/kyowa-kirin/)

---
JSON: https://onco.cc/api/v1/entities/nct07623616.json